(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 July 2004 (15.07.2004)

PCT

(10) International Publication Number
WO 2004/058255 A1

(51) International Patent Classification[7]: A61K 31/426, C07D 277/56, 417/12, 417/04, A61K 31/427, A61P 25/28

(21) International Application Number:
PCT/GB2003/005542

(22) International Filing Date:
18 December 2003 (18.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0230087.9 24 December 2002 (24.12.2002) GB

(71) Applicant *(for all designated States except MG, US)*: **ASTRAZENECA AB** [SE/SE]; Sodertalje, S-151 85 (SE).

(71) Applicant *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BERGGREN, Anna, Ingrid, Kristina** [SE/SE]; AstraZeneca R & D Molndal, Molndal, S-431 83 (SE). **BOSTROM, Stig, Jonas** [SE/SE]; AstraZeneca R & D Molndal, Molndal, S-431 83 (SE). **ELEBRING, Stig, Thomas** [SE/SE]; AstraZeneca R & D Molndal, Molndal, S-431 83 (SE). **FALLEFORS, Linda** [SE/SE]; AstraZeneca R & D Molndal, Molndal, S-431 83 (SE). **WILSTERMANN, Johan, Michael** [SE/SE]; AstraZeneca R & D Molndal, Molndal, S-431 83 (SE). **GREASLEY, Peter** [GB/SE]; AstraZeneca R & D Molndal, S-431 83 Molndal (SE).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, P O Box 272, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4GR (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(regional)*: ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/058255 A1

(54) Title: 4, 5-DIARYLTHIAZOLE DERIVATIVES AS CB-1 LIGANDS



(I)

(57) Abstract: The present invention relates to compounds of formula (I): in which R^1 and R^2 independently represent phenyl, thienyl or pyridyl and R^3represents a group -X-Y-NR^4R^5 in which X is CO or SO_2; Y is absent or represents NH and the other substituente are as defined in the description and their use in the treatment of obesity, psychiatric and neurological disorders and to pharmaceutical compositions containing them.

THERAPEUTIC AGENTS

Field of invention

The present invention relates to certain 4,5 –diarylthiazole-2-carboxamide compounds, to processes for preparing such compounds, to their use in the treatment of obesity, psychiatric and neurological disorders, and to pharmaceutical compositions containing them.


Background of the invention

It is known that certain CB_1 modulators (known as antagonists or inverse agonists) are useful in the treatment of obesity, psychiatric and neurological disorders (WO01/70700 and EP 656354). However, there is a need for CB_1 modulators with improved physicochemical properties and/or DMPK (distribution, metabolism and pharmacokinetic) properties and/or pharmacodynamic properties.

Certain *N*-acyl-4,5 –diarylthiazoles-2-alkylamines and *N*-acyl-4,5 –diarylthiazoles-2-carboxamides are reported to have antithrombotic activity in EP388909 and EP 377457. Other such thiazoles are disclosed in British Journal of Pharmacology (2002), 135(3), 782-788;European Journal of Pharmacology (2000), 391(1/2), 49-54 ;Bioorganic & Medicinal Chemistry (1999), 7(8), 1559-1565; WO9420475; WO9420476; Journal of Medicinal Chemistry (1994), 37(8), 1189-99; Journal of Pharmacology (1993), 243(2), 179-84; European Journal of Pharmacology (1993 Oct 19), 243(2), 179-84; and the Journal of Medicinal Chemistry (1994 Apr 15), 37(8), 1189-99. The compounds disclosed in these documents are disclaimed from the compound claims of the present invention.

Description of the invention

The invention relates to compounds of the general formula (I)



I

and pharmaceutically acceptable salts, prodrugs and solvates thereof, in which

R^1 and R^2 independently represent phenyl, thienyl or pyridyl each of which is optionally substituted by one , two or three groups represented by Z;

Z represents a C_{1-6}alkyl group, a C_{1-6}alkoxy group, hydroxy, halo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, trifluoromethylsulphonyl, nitro, amino, mono or di C_{1-3}alkylamino, mono or di C_{1-3}alkylamido, C_{1-3}alkylsulphonyl, C_{1-3}alkoxycarbonyl, carboxy,